The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Cancers After Solid Organs Transplants
Official Title: Epidemiological, Immunological, Pathological and Pharmacogenetic Study of Cancers Occuring After Solid Organs Transplants
Study ID: NCT00948883
Brief Summary: About 1500 solid organs transplants are performed each year in the Paris agglomeration. Cancer risk in the transplanted is about three times higher than in a population of the same age without any organ transplant. Thus cancer is an important problem for organ transplant. These cancers can be related to many factors : * Post-transplant cancers are due in part to the non specific immunosuppression, which leads to oncogenic viruses replication, and then produces virus inducted cancers (as lymphoma due to EBV virus). * Post-transplant cancers can also be due to the carcinogenic factors of the immunosuppressive drugs (as cyclosporine or tacrolimus, which can cause the appearance of metastases). However, a new type of immunosuppressive drugs (mTOR inhibitors) appear to have anti-cancer properties. * Post-transplant cancers which are not virus-inducted can be relied to genetic factors of the transplanted patient and/or the transplant donor. There are 4 axes in this study : * Axis 1 : Epidemiological, clinical and biological study of the incident cancers in transplanted patients. * Axis 2 : Qualitative and quantitative immunological study of lymphocyte cells by the transplanted patient (determine their characteristics when a cancer appears). * Axis 3 : Pathological and genetic study of the post-transplant cancer cells (see if the cancer is caused by the donor or the recipient). Creation of a biobank. * Axis 4 : Pharmacogenetic study of the immunosuppressive drugs (determine the impact of patient genetic variability on tolerance and efficiency of the immunosuppressive drugs).
Detailed Description: This is an observational and comparative study (2 control patients are recruited for each 1 case patient). A case patient is a patient who has developed a cancer after his/her transplant. A control patient is a patient who has not developed a cancer after his/her transplant. These 2 groups will be matched according to specific inclusion criteria.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
H么pital Bic锚tre - Assistance Publique-H么pitaux de Paris, Le Kremlin Bicetre Cedex, , France
Name: Michel MARTY, MD
Affiliation: Assistance Publique - H么pitaux de Paris
Role: PRINCIPAL_INVESTIGATOR